Medication vs Medication
Saxenda vs Orlistat
A practical UK comparison focused on what is genuinely different — not which brand has the loudest marketing.
Liraglutide (Saxenda / licensed equivalents)
Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo
Orlistat
Typically produces more modest average loss than GLP-1/GIP medicines; individual response varies
Side-by-side
| Liraglutide (Saxenda / licensed equivalents) | Orlistat | |
|---|---|---|
| Active ingredient | liraglutide | orlistat |
| Form | Daily injection | Capsule with meals |
| Frequency | Once daily | Up to three times daily with fat-containing meals |
| Licence | UK weight management licence | UK weight management licence |
| NHS context | NICE option in specialist services for defined groups; pathway availability varies | Long-established NHS option; prescribing criteria and local practice apply |
| Evidence | Mature | Very mature |
| Weight-loss evidence | Large adult trial: mean -8.0% at 56 weeks vs -2.6% placebo | Typically produces more modest average loss than GLP-1/GIP medicines; individual response varies |
| Maintenance | Ongoing treatment and maintenance strategy matter | Can be continued where effective/tolerated; diet composition affects tolerability |
| GI considerations | GI effects common; daily dosing can add burden | GI effects are closely related to dietary fat intake |
Reasons to discuss Liraglutide (Saxenda / licensed equivalents)
- Longer track record in obesity treatment
- GLP-1 mechanism
- Can be appropriate where other options are unsuitable
- Licensed specifically for weight management
Trade-offs
- Daily injection
- Lower average weight loss than newer weekly incretin treatments
- NHS use is restricted
- Daily adherence burden
Reasons to discuss Orlistat
- Needle-free
- Generic and established
- Different mechanism from incretin medicines
- Usually lower drug cost than branded incretin therapy
Trade-offs
- Lower average efficacy
- Oily stools/urgency and other GI effects can be disruptive
- Must be taken around fat-containing meals
- Fat-soluble vitamin considerations
Which is stronger for weight loss?
Liraglutide (Saxenda / licensed equivalents) is rated 5/10 and Orlistat 3/10 in our comparison framework. That rating summarises the obesity evidence available for the licensed formulation; it is not a prediction of your result.
Which is easier to live with?
Liraglutide (Saxenda / licensed equivalents): Once daily. Orlistat: Up to three times daily with fat-containing meals. For some people a weekly injection is easier than a daily tablet; for others avoiding a needle is decisive.
NHS vs private reality
NICE option in specialist services for defined groups; pathway availability varies. Long-established NHS option; prescribing criteria and local practice apply. NICE criteria and NHS availability are related but not identical, so check the current pathway rather than assuming a clinically eligible medicine is immediately available through a GP.
Maintenance matters
Ongoing treatment and maintenance strategy matter. Can be continued where effective/tolerated; diet composition affects tolerability. A treatment comparison that ends at the point of weight loss is incomplete.
Questions to ask a prescriber
- Which option is actually licensed and clinically appropriate for my health history?
- How do the expected benefits compare for someone with my diabetes/cardiovascular history?
- What side effects should make me contact you?
- What will monitoring involve?
- What is the plan if I cannot tolerate the maintenance dose?
- What happens if I stop?
Sources
Continue exploring